Xuejun Chen

A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: A Children's Oncology Group phase 1 consortium study (ADVL1011)

Mignon L. Loh, Sarah K. Tasian, Karen R. Rabin et al. · Pediatric Blood & Cancer · 2015 · 127 citations

Medicine, Oncology, Pharmacology +17

Parsaclisib, a potent and highly selective PI3Kδ inhibitor, in patients with relapsed or refractory B-cell malignancies

Andres Forero‐Torres, Radhakrishnan Ramchandren, Abdulraheem Yacoub et al. · Blood · 2019 · 100 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +9

First-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumors

Elizabeth J. Davis, Juan Martín-Liberal, Rebecca Kristeleit et al. · Journal for ImmunoTherapy of Cancer · 2022 · 93 citations · Full text

Medicine, Oncology, Pharmacology +16

Pharmacokinetics of Ruxolitinib in Patients with Atopic Dermatitis Treated With Ruxolitinib Cream: Data from Phase II and III Studies

Xiaohua Gong, Xuejun Chen, Michael E. Kuligowski et al. · American Journal of Clinical Dermatology · 2021 · 73 citations · Full text

Medicine, Dermatology, Pharmacology +17

Phase 1 study of the PI3Kδ inhibitor INCB040093 ± JAK1 inhibitor itacitinib in relapsed/refractory B-cell lymphoma

Tycel Phillips, Andres Forero‐Torres, Taimur Sher et al. · Blood · 2018 · 55 citations · Full text

Medicine, Oncology, Pharmacotherapy +9